ORIGINAL INVESTIGATION. Effect of Cholecalciferol Plus Calcium on Falling in Ambulatory Older Men and Women

ORIGINAL INVESTIGATION Effect of Cholecalciferol Plus Calcium on Falling in Ambulatory Older Men and Women A 3-Year Randomized Controlled Trial Heike A. Bischoff-Ferrari, MD, MPH; E. John Orav, PhD; Bess Dawson-Hughes, MD Background: A recent meta-analysis found that cholecalciferol (vitamin D) should reduce falls by more than %. However, little is known about whether supplemental cholecalciferol plus calcium citrate malate will lower the long-term risk of falling in men, active older individuals, and older individuals with higher 25- hydroxyvitamin D levels. Methods: We studied the effect of 3-year supplementation with cholecalciferol-calcium on the risk of falling at least once in 199 men and 246 women 65 years or older and living at home. Individuals received IU of cholecalciferol plus mg of calcium citrate malate per day or placebo in a randomized double-blind manner. Subjects were classified as less physically active if physical activity was below the median level. Low 25- hydroxyvitamin D levels were classified as those below 32 ng/ml ( nmol/l). Results: In 3 years, 55% of women and 45% of men reported at least 1 fall. Mean±SD baseline 25- hydroxyvitamin D levels were 26.6±12.7 ng/ml (66.4±31.7 nmol/l) in women and 33.2±14.2 ng/ml (82.9±34.9) in men. Cholecalciferol-calcium significantly reduced the odds of falling in women (odds ratio [OR],.54; 95% confidence interval [CI],.-.97), but not in men (OR,.93; 95% CI,.-1.72). Fall reduction was most pronounced in less active women (OR,.35; 95% CI,.15-.81). Baseline 25-hydroxyvitamin D level did not modulate the treatment effect. Conclusions: Long-term dietary cholecalciferolcalcium supplementation reduces the odds of falling in ambulatory older women by 46%, and especially in less active women by 65%. Supplementation had a neutral effect in men independent of their physical activity level. Arch Intern Med. 6;166:424-4 Author Affiliations: Department of Rheumatology and Institute for Physical Medicine, University Hospital Zurich, Zurich, Switzerland (Dr Bischoff-Ferrari); and Departments of Nutrition (Dr Bischoff-Ferrari), Clinical Epidemiology (Dr Orav), and Biostatistics (Dr Orav), Harvard School of Public Health, and Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University (Dr Dawson-Hughes), Boston, Mass. OUR GROUP HAS RECENTLY documented in a metaanalysis of 5 randomized controlled trials including 1237 individuals that cholecalciferol (vitamin D) supplementation in any form should prevent more than % of falls in older persons. 1 However, subgroup analyses could not definitely address whether this effect of cholecalciferol differed by sex, activity level, or baseline levels of 25- hydroxyvitamin D (25-OHD). Men and women may benefit differently from a given dose of cholecalciferol, as generally ambulatory older men have higher 25-OHD levels, 2,3 are more physically active, 3 have greater muscle strength, 4 and fall less often 5-7 than ambulatory older women. Furthermore, previous randomized controlled trials 8- with supplemental cholecalciferol plus calcium were limited to short follow-up periods ranging from 3 to 12 months. Four lines of evidence support a beneficial effect of vitamin D on muscle and falls. First, proximal muscle weakness is a prominent feature of the clinical syndrome of vitamin D deficiency, 11,12 and muscle weakness is a major risk factor for falls in older persons. 13 Second, highly specific receptors for 1,25-dihydroxyvitamin D are expressed in human muscle tissue, 11,14 decline with age, 15 and promote protein synthesis. 14,16 Third, a vitamin D receptor dependent action of vitamin D on muscle is supported by findings in mice with the gene for the vitamin D receptor deleted, in which the absence of the gene causes muscle abnormalities. 17 Fourth, several observational studies point toward a positive association between levels of 25- OHD 3,18,19 or 1,25-dihydroxyvitamin D 4 and muscle strength or lower extremity function in older persons. The aim of this study was to investigate a person s risk of falling given longterm supplementation with cholecalciferol- 424

calcium compared with placebo in older individuals living in the community. Subgroups of interest were men and women, active and less active individuals, and individuals with lower and higher baseline 25-OHD levels. METHODS SUBJECTS We enrolled healthy ambulatory men and women 65 years or older and living in the community. Of 848 persons who underwent prescreening with questionnaires, 545 were invited for screening. The final study sample included 445 individuals, of whom 4 were white, 11 were black, and 4 were Asian. All participants provided written informed consent, and the study protocol was approved by the Human Investigation Review Committee at Tufts University, Boston, Mass. EXCLUSION CRITERIA Subjects receiving therapy consisting of bisphosphonate, calcitonin, estrogen, tamoxifen citrate, or testosterone in the past 6 months or fluoride in the past 2 years; those with a history of renal disease or renal stone in the past 5 years; and those with current cancer, hyperparathyroidism, dietary calcium intake exceeding 1 mg/d, or laboratory evidence of kidney (serum creatinine level, 1.2 mg/dl [ 6.1 µmol/l]) or liver disease were excluded. Additional exclusion criteria were published previously. STUDY DESIGN This was a 3-year double-blind placebo-controlled trial. The study was originally designed and powered to study the effect of cholecalciferol-calcium on bone mineral density. In this analysis, we study the effect of cholecalciferol-calcium on a secondary outcome of the original trial, a person s risk of falling at least once during follow-up. Participants were randomly assigned to receive cholecalciferol (vitamin D 3 ; IU/d) plus calcium citrate malate ( mg/d) or placebo. Random group assignment was performed with stratification according to sex, race, and decade of age. Participants were asked to terminate any additional calcium or cholecalciferol supplements 2 months before the study start and throughout the study. Tablets in both groups had an identical appearance and were taken once daily at bedtime. FOLLOW-UP AND COMPLIANCE Of 445 subjects who were randomized, 389 attended the 3-year follow-up visit, and 318 were still receiving study medication at the 3-year follow-up visit. One hundred twenty-seven subjects discontinued treatment (4 died, stopped for personal reasons, 46 withdrew because of illness, 17 started estrogen or glucocorticoid therapy, and had problems with the study medication). Compliance was assessed on the basis of pill counts. FALL DEFINITION AND ASCERTAINMENT Participants were asked to send a postcard after every fall, which was then followed by a telephone call from a staff member to assess the circumstances of the fall. In addition, falls were ascertained at every follow-up visit. Falls were defined as unintentionally coming to rest on the ground, floor, or other lower level. 21 The primary analysis included any first fall event. In a sensitivity analysis, we restricted the analyses further to persons with a low-trauma fall. Low-trauma falls were defined as occurring from a standing or sitting position; while standing, sitting, walking; and while walking and turning on ground level. For the total number of falls, predefined fall categories were used in addition to the total sum of falls, including 1, 2, 3 or 4, and more than 4 times during the 3-year follow-up. MEASUREMENTS Throughout the 3-year trial, subjects were invited to the study center every 6 months for a follow-up visit (6 visits). Information on calcium and cholecalciferol intake was obtained by a food frequency questionnaire. 22 For calcium intake, we used the average calcium intake across all follow-up visits. Baseline body mass index was measured as weight in kilograms divided by the square of the height in meters at the study center. Physical activity included leisure, household, and occupational activity as estimated by the Physical Activity Scale for the Elderly questionnaire. 23 Scores on this questionnaire were previously found to be positively associated with grip strength (r =.37), static balance (r=.33), and leg strength (r=.25) in older persons. 23 We classified subjects as less physically active if their activity level was below the median of average physical activity (Physical Activity Scale for the Elderly score, 9) measured across time at each follow-up visit. Tobacco use and use of alcoholic beverages were assessed by a questionnaire at baseline. Comorbid conditions assessed at baseline with a questionnaire were summarized with a comorbidity score, which represents the sum of the following conditions: diabetes mellitus, hyperthyroidism, hypertension, cancer, low back surgery, previous hip fracture, and stomach surgery. LABORATORY INVESTIGATIONS Venous blood was collected between 7 and 9: AM, after the subjects had fasted for at least 8 hours for measurement of plasma 25-OHD levels (by a competitive protein binding assay as described by Preece et al 24 ) and serum intact parathyroid hormone levels (by immunometric assay; Nichols Institute, San Juan Capistrano, Calif). For the stratified analysis on baseline 25-OHD levels, low serum 25-OHD levels were defined as below 32 ng/ml ( nmol/l), which is a commonly used cutoff level. 25,26 Baseline creatinine clearance was calculated as [urinary creatinine concentration (in milligrams per deciliter) urine volume (in milliliters)]/[plasma creatinine (in milligrams per deciliter) 14 minutes]. STATISTICAL ANALYSIS The main intent-to-treat analysis included 445 subjects. We used logistic regression to evaluate the effect of cholecalciferol-calcium compared with placebo on a person s risk of falling at least once during the 3-year follow-up. This approach was chosen to be consistent with the outcome evaluated in the recent meta-analysis from our group. 1 All analyses controlled for age in years, sex, baseline body mass index ( 25, 25-29, or ), average dietary calcium intake across time, baseline plasma 25-OHD levels, baseline plasma intact parathyroid hormone levels, being less vs more active, baseline smoking status (never, current, or former smoker), baseline use of alcoholic beverages (yes or no), baseline 425

Table 1. Baseline Study Characteristics of the 445 Study Subjects* Characteristic Placebo Group (n = 125) Women (n = 246) Men (n = 199) Cholecalciferol- Calcium Group (n = 121) Placebo Group (n = 1) Baseline Comparison by Treatment and Cholesterol- Sex, P Value Cadcium Group (n = 98) Women Men Age, y 71 ± 5 71 ± 5 71 ± 5 ± 4.41.39 BMI 26.8 ± 4.7 26.6 ± 4. 26.9 ± 3.5 27.1 ± 3.2.75.71 Dietary calcium intake, mg/d 79 ± 363 686 ± 292 667 ± 347 738 ± 391.14.18 Dietary vitamin D intake, IU/d 1 ± 111 173 ± 9 195 ± 118 199 ± 6..28 25-OHD level, ng/ml 25.2 ± 12.1 28. ± 13.2 33.2 ± 13.4 32.8 ± 15..9.84 Intact PTH level, pg/ml. ± 17.7 38.5 ± 15.7 34.7 ± 14.3 37. ± 18.5.48.34 Creatinine clearance, ml/min 83.5 ±.3 81.5 ± 24.4 4.1 ± 28. 7.7 ± 26.7.48.78 PASE score (No. [%] of less 7 ± 53 (71 [57]) 4 ± 47 (68c [67]) 122 ± 55 ( []) 126 ± 59 ( [41]).62.63 active persons) Current smoker, % 5 9 5 7.35.53 Former smoker, % 58 Drink alcoholic beverages, % 34 35 26 27.85.9 No. of comorbid conditions, % None 56 54 48 52.28.16 1 36 35 42 38 2 6 9 8 3 2 1 1 2 Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); 25-OHD, 25-hydroxyvitamin D; PASE, Physical Activity Scale for the Elderly; PTH, parathyroid hormone. SI conversion factors: To convert creatinine clearance to milliliters per second, multiply by.167; to convert 25-OHD to nanomoles per liter, multiply by 2.496. *Ninety-seven percent of all enrolled subjects were white. Unless otherwise indicated, data are expressed as mean ± SD. Indicates from food sources only. Table 2. Change in Plasma 25-OHD During 3-Year Treatment in 445 Subjects* 25-OHD Level, Mean ± SD, ng/ml (No. of Patients) Cholecalciferol-Calcium Group Placebo Group Subjects Baseline 3-Year Follow-up Baseline 3-Year Follow-up Women 28. ± 13.2 (n = 121) 41.6 ± 16.7 (n = 99) 25.2 ± 12.1 (n = 124) 27.2 ± 13. (n = 9) Men 32.8 ± 15. (n = 98) 44. ± 13.6 (n = 83) 33.2 ± 13.4 (n = 1).6 ±.9 (n = 86) Women less active 28.4 ± 14.2 (n = 53) 41.4 ± 14.1 (n = 46) 24.2 ± 9.8 (n = 54) 29.7 ± 14.4 (n = 47) Women more active 27.7 ± 12.5 (n = 68) 41.8 ± 17.9 (n = 53) 26. ± 13.6 (n = ) 25.2 ± 11.5 (n = 62) Men less active.2 ± 14.2 (n = ) 44. ± 13.7 (n = 34).6 ± 12.3 (n = ) 28.7 ± 9.3 (n = 31) Men more active 34.4 ± 15.5 (n = 58) 44. ± 13.7 (n = 49) 34.8 ± 13.9 (n = 61) 31.8 ± 11.6 (n = 55) Abbreviations: 25-OHD, 25-hydroxyvitamin D; PTH, parathyroid hormone. SI conversion factor: To convert 25-OHD to nanomoles per liter, multiply by 2.496. *The results are consistent with good treatment compliance in the intervention group. number of comorbid conditions, baseline creatinine clearance, and length of follow-up (in days). All 445 subjects underwent analysis, followed by subgroup analyses by sex, activity level, and baseline serum 25-OHD levels. Subgroup analyses were predefined on the basis of clinical considerations and previous findings. Because the study was not powered to detect effect modification, the interaction terms for sex, activity level, and baseline 25-OHD level did not reach statistical significance (treatment sex, P =.25; treatment activity level, P=.29; treatment 25-OHD level, P=.71). We considered as a secondary outcome the occurrence of any low-trauma fall. Because the effect of cholecalciferol was similar to that of the analyses including all falls, only the results for the primary outcome are presented. All analyses were conducted with SAS statistical software (version 8.2; SAS Institute Inc, Cary, NC). All P values were 2 sided. RESULTS Baseline characteristics were similar between assigned treatment groups among men and women (Table 1). Changes in plasma 25-OHD levels over time are presented by sex, activity level, and treatment in Table 2. FALLS DURING FOLLOW-UP BY SEX AND ACTIVITY LEVEL Overall, 97 men (49%) and 134 women (55%) fell during the 3-year follow-up. Of these, 123 (53%) of all first falls occurred in the first year, 62 (27%) in the second year, and 46 (%) in the third year. Among women, 69 426

(%) of the less active and 65 (61%) of the more active individuals fell. Among men, 36 (46%) of the less active and (%) of the more active individuals fell. TREATMENT EFFECT DURING THE 3-YEAR FOLLOW-UP Intent-to-Treat Analysis In 3 years, including men and women, 231 of 445 individuals reported at least 1 fall. Of these, 7 were in the cholecalciferol-calcium group and 124 were in the placebo group. In the multivariate analysis (Table 3), cholecalciferol-calcium did not significantly reduce the odds of falling compared with placebo in the total sample (odds ratio [OR],.77; 95% confidence interval [CI],.51-1.15). Among women, 134 of 246 individuals reported at least 1 fall. Of these, 59 were in the cholecalciferol-calcium group and 75 were in the placebo group. In the multivariate analysis, cholecalciferol-calcium significantly reduced the odds of falling in women by 46% compared with placebo (OR,.54; 95% CI,.-.97). Fall reduction was most pronounced in less active women (OR,.35; 95% CI,.15-.81) rather than in active women (OR, 1.6; 95% CI,.42-2.66). Among men, 97 of 199 individuals reported at least 1 fall. Of these, 48 were in the cholecalciferol-calcium group and 49 were in the placebo group. In the multivariate analysis, cholecalciferol-calcium did not reduce the odds of falling in men compared with placebo (OR,.93; 95% CI,.-1.72). Unlike the findings in women, we found no appreciable impact regarding the level of responsiveness to treatment in less active men (OR,.96; 95% CI,.34-2.67) compared with more active men (OR, 1.1; 95% CI,.43-2.). Fall reduction by cholecalciferol-calcium was not enhanced further in individuals with low 25-OHD levels. If only subjects with 25-OHD levels of less than 32 ng/ml ( nmol/l) underwent analysis (64% of participants), this corresponded to an OR of.73 (95% CI,.43-1.25) vs.77 for the total sample. If only women with 25-OHD levels of less than 32 ng/ml underwent analysis (74% of women), this corresponded to an OR of.55 (95% CI,.28-1.) vs.54 in for all women. Similar results were achieved using a lower cutoff of 24 ng/ml (59.9 nmol/l) (39% of all participants). Per Protocol Analysis If analyses were restricted to individuals who continued to receive the study medication until the end of followup, the study sample included 318 subjects. In the per protocol analysis, receiving treatment enhanced the cholecalciferol-calcium benefit significantly for less active individuals, women, and especially less active women (Table 3). Creatinine Clearance, Intact Parathyroid Hormone Level, and Risk of Falling Using creatinine clearance as a linear variable and a dichotomized variable ( 65 or 65 ml/min [ 1.1 or 1.1 Table 3. Effect of Cholecalciferol-Calcium on the Number of Persons Who Fell During the 3-Year Follow-up Patients Intent-to-Treat Analysis (n = 445) ml/s], as suggested by Dukas et al 27,28 ), we could not find that creatinine clearance predicted the risk of falling or modified the treatment effect of cholecalciferolcalcium. Similarly, we found no independent effect of parathyroid hormone on the incidence of falls. Time Course of Response to Treatment In Figure 1 and Figure 2, the time course of response to treatment is illustrated in 318 subjects who continued to receive treatment until the end of follow-up. Women and especially less active women who received cholecalciferol-calcium had lower rates of falls after 12 months of treatment. Treatment Effect on Total Number of Falls in 445 Individuals The total number of falls was similar between treatment groups for women (cholecalciferol-calcium, 164 falls among 121 women; placebo, 142 falls among 125 women) and men (cholecalciferol-calcium, 1 falls among 98 men; placebo, 1 falls among 1 men). The results in women are primarily due to the fact that most women who had more than 4 falls were in the cholecalciferolcalcium group. Those who fell frequently were equally distributed in the active women (2 women in the cholecalciferol-calcium group and 2 in the placebo group), whereas of the 6 inactive women who had more than 4 falls, 5 were in the cholecalciferol-calcium group. COMMENT OR (95% CI)* Per Protocol Analysis (n = 318) Total sample.77 (.51-1.15) (n = 416).68 (.43-1.8) (n = 318) Less active. (.33-1.7) (n = 4).42 (.-.87) (n = 146) More active.98 (.54-1.77) (n = 212).88 (.46-1.68) (n = 172) Women.54 (.-.97) (n = 229).44 (.21-.9) (n = 1) Less active.35 (.15-.81) (n = 1).26 (.9-.83) (n = 91) More active 1.6 (.42-2.66) (n = 99).88 (.31-2.55) (n = 79) Men.93 (.-1.72) (n = 187).84 (.42-1.66) (n = 148) Less active.96 (.34-2.67) (n = 74).65 (.18-2.29) (n = 55) More active 1.1 (.43-2.) (n = 113).94 (.37-2.38) (n = 93) Abbreviations: CI, confidence interval; OR, odds ratio. *Controlling for age, sex, body mass index, average dietary calcium intake, baseline 25-hydroxyvitamin D levels, baseline intact parathyroid hormone level, activity level, smoking status, use of alcoholic beverages, number of comorbid conditions, creatinine clearance, and length of follow-up. During this 3-year community-based study, supplementation with cholecalciferol-calcium significantly reduced the odds of falling by 46% among women, whereas no appreciable benefit was observed in men. This sex difference in response to cholecalciferol-calcium has not been addressed specifically in previous trials because primar- 427

A B Cholecalciferol-Calcium (n = 77) Placebo (n = 93) Cholecalciferol-Calcium (n = 71) Placebo (n = 77) 6 12 18 24 36 6 12 18 24 36 Figure 1. Cumulative percentage of falls by treatment group and sex. A, The women who received cholecalciferol (vitamin D) plus calcium citrate malate had lower rates of falls starting after 12 months and then throughout the follow-up compared with women in the placebo group. B, In men, both groups had similar rates of falls throughout the study. A B Cholecalciferol-Calcium (n = 38) Placebo (n = 53) Cholecalciferol-Calcium (n = 97) Placebo (n = ) 6 12 18 24 36 6 12 18 24 36 C D Cholecalciferol-Calcium (n = 28) Placebo (n = 27) Cholecalciferol-Calcium (n = 43) Placebo (n = ) 6 12 18 24 36 6 12 18 24 36 Figure 2. Cumulative percentage of falls by treatment group and activity level. A, Less active women who received cholecalciferol (vitamin D) plus calcium citrate malate had lower rates of falls starting after 12 months and then throughout the follow-up compared with women in the placebo group. B, In more active women, both groups had similar rates of falls throughout the study. C and D, In less active (C) and more active (D) men, the rate of falls was not consistently lower in the cholecalciferol-calcium group or the placebo group. ily women were studied. 1,9,29 One explanation may be that ambulatory women have lower muscle strength and an increased susceptibility to falls than ambulatory men. 5-7 Only among less active men who stayed on treatment could a possible benefit not be excluded. However, this result was not significant. Cholecalciferol-calcium supplementation was more successful in reducing falls among less active individuals, and primarily among less active women with a 65% fall reduction. This benefit was enhanced among less active women who continued to receive treatment throughout the 3-year follow-up, leading to a 74% fall reduction. This may pos- 428

sibly be related to lower muscle strength in less active women, but it cannot be attributed to lower 25-OHD levels because less active women did not have lower baseline 25-OHD levels than more active women.,31 On the other hand, the relationship between activity level and treatment response is somewhat complicated by the observed increased frequency of falls in more active individuals in our study. An increased risk of falling in more active community-dwelling older persons has been described before, 7,32 suggesting that more active older persons may put themselves at increased risk for falls simply through being more active, 7,32 a mechanism that may not be affected significantly by cholecalciferol-calcium supplementation. Based on our results, length of treatment with cholecalciferol-calcium may be an important factor. The treatment effect in women in our study increased with time and occurred primarily after 12 months of treatment. On the other hand, the short-term benefits of cholecalciferolcalcium on the risk of falling observed in 2 previous European RCTs may be explained by a combination of older age, increased frailty, and significantly lower baseline 25- OHD levels in their participants. 8,9 In those 2 studies, with follow-up ranging from 3 to 12 months and including a total of 259 elderly women, a similar dose of cholecalciferol ( IU/d) plus a higher dose of calcium carbonate ( mg/d) reduced the odds of falling by 35% (pooled OR,.65; 95% CI,.-1. 1 ) compared with calcium carbonate alone ( mg/d). With a 3-year follow-up, we documented a greater effect of cholecalciferol-calcium with a significant 46% fall reduction among women. We did not find that lower baseline 25-OHD levels at any cutoff level ( 24 ng/ml [ 59.9 nmol] or 32 ng/ml [ nmol/l]) modified the treatment response of cholecalciferol-calcium in our study. This may be explained by the rather high mean baseline 25-OHD levels observed in our participants, which is likely owing to vitamin D fortification of dairy products and activity level of our healthy and relatively young communitydwelling older participants. Total number of falls was not significantly reduced by cholecalciferol-calcium treatment in men or women. However, among women, this was primarily influenced by those who fell frequently and did not seem to benefit from treatment. Most women who fell more than 4 times during treatment were in the less active subgroup, suggesting that these women may have additional problems that make them fall independent of cholecalciferol-calcium therapy. The strengths of this study include its double-blind, randomized, placebo-controlled design and its longterm follow-up. Although falls were a secondary outcome of the original trial, this end point was ascertained comprehensively through postcards and at every 6-month follow-up visit. This is important because falls tend to be forgotten if no injuries are involved. 33 Our result for the overall sample is consistent with the previous crude findings based on 389 subjects in the original publication that found no significant benefit of cholecalciferolcalcium on the percentage of persons who fell. However, by focusing on predefined subgroups, we have demonstrated that women, and especially less active women, benefit significantly from cholecalciferolcalcium supplementation. The frequency of falls in our ambulatory study sample is representative of what has been reported in the literature. 5-7,32 Also, the median level of physical activity is similar to what has been described before in the community-dwelling elderly population. 34 Furthermore, in addition to the protection conferred by randomization, we were able to control for several potential confounders and variables known to influence the risk of falling in older persons. In addition, the per protocol analysis shows an enhanced treatment effect for the less active individuals, women, and especially less active women, which would be expected if there is a true treatment effect by cholecalciferol-calcium. There are also limitations to our study. Our main findings pertain to subgroups, which is an approach that may be questioned because the trial was not originally powered to detect effect modification by sex, activity level, and baseline 25-OHD level. However, as stated in the introduction, our focus on these subgroups was based on previously reported data indicating that these subgroups may benefit differently from treatment. Moreover, generalizability may be limited to communitydwelling older persons. Our results have clinical significance. First, we show a significant reduction in the odds of falling in ambulatory older women with a very inexpensive, well-tolerated, and simple supplementation with cholecalciferol-calcium. Second, our findings fit well with the results of the original trial, which showed a significant % reduction of osteoporotic fractures with cholecalciferol-calcium compared with placebo, with most of the fractures occurring in women. Third, the benefits of this intervention are similar to or greater than those of more expensive and more timeintensive interventions, such as medication adjustments and occupational therapy, 21,35 and single-intervention strategies, such as tai chi balance training 36 and exercise, 37 that reduced the risk of falling from 25% to %. In conclusion, cholecalciferol-calcium supplementation reduces falls by 46% to 65% in community-dwelling older women, but has a neutral effect on falls in men. Accepted for Publication: June 23, 5. Correspondence: Heike A. Bischoff-Ferrari, MD, MPH, Department of Rheumatology and Institute for Physical Medicine, University Hospital Zurich, Gloriastrasse 25, 91 Zurich, Switzerland (Heike.Bischoff@usz.ch). Financial Disclosure: None. Funding/Support: This study was supported by a grant from the Charles H. Farnsworth Trust, Boston, Mass (US Trust Company, trustee), and by grant AG353 from the National Institutes of Health, Bethesda, Md. REFERENCES 1. Bischoff-Ferrari HA, Dawson-Hughes B, Willett CW, et al. Effect of vitamin D on falls: a meta-analysis. JAMA. 4;291:1999-6. 2. Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR. Serum 25- hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone. 2;:771-777. 3. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged y. Am J Clin Nutr. 4;:752-758. 4. Bischoff HA, Stahelin HB, Urscheler N, et al. Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil. 1999;:54-58. 429

5. Tinetti ME. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319:11-17. 6. Prudham D, Evans JG. Factors associated with falls in the elderly: a community study. Age Ageing. 1981;:141-146. 7. Vellas BJ, Wayne SJ, Romero LJ, Baumgartner RN, Garry PJ. Fear of falling and restriction of mobility in elderly fallers. Age Ageing. 1997;26:189-193. 8. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a shortterm vitamin D 3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 1;86: 1633-1637. 9. Bischoff HA, Stahelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res. 3;18: 343-351.. Graafmans WC, Ooms ME, Hofstee HM, Bezemer PD, Bouter LM, Lips P. Falls in the elderly: a prospective study of risk factors and risk profiles. Am J Epidemiol. 1996;143:1129-1136. 11. Boland R. Role of vitamin D in skeletal muscle function. Endocr Rev. 1986;7: 434-447. 12. Glerup H, Mikkelsen K, Poulsen L, et al. Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Int. ; 66:419-424. 13. Moreland JD, Richardson JA, Goldsmith CH, Clase CM. Muscle weakness and falls in older adults: a systematic review and meta-analysis. J Am Geriatr Soc. 4;52:1121-1129. 14. Sorensen OH, Lund B, Saltin B, et al. Myopathy in bone loss of ageing: improvement by treatment with 1 alpha-hydroxycholecalciferol and calcium. Clin Sci (Lond). 1979;56:157-161. 15. Bischoff-Ferrari HA, Borchers M, Gudat F, Durmuller U, Stahelin HB, Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res. 4;19:265-269. 16. Haddad JG, Walgate J, Min C, Hahn TJ. Vitamin D metabolite-binding proteins in human tissue. Biochim Biophys Acta. 1976;444:921-925. 17. Endo I, Inoue D, Mitsui T, et al. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology. 3;144:5138-5144. 18. Mowe M, Haug E, Bohmer T. Low serum calcidiol concentration in older adults with reduced muscular function. J Am Geriatr Soc. 1999;47:2-226. 19. Dhesi JK, Bearne LM, Moniz C, et al. Neuromuscular and psychomotor function in elderly subjects who fall and the relationship with vitamin D status. J Bone Miner Res. 2;17:891-897.. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337:6-676. 21. Buchner DM, Hornbrook MC, Kutner NG, et al. Development of the common data base for the FICSIT trials. J Am Geriatr Soc. 1993;41:297-8. 22. Krall EA, Sahyoun N, Tannenbaum S, Dallal GE, Dawson-Hughes B. Effect of vitamin D intake on seasonal variations in parathyroid hormone secretion in postmenopausal women. N Engl J Med. 1989;321:1777-1783. 23. Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46: 153-162. 24. Preece MA, O Riordan JL, Lawson DE, Kodicek E. A competitive protein-binding assay for 25-hydroxycholecalciferol and 25-hydroxyergocalciferol in serum. Clin Chim Acta. 1974;54:235-242. 25. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7:439-443. 26. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338:777-783. 27. Dukas L, Schacht E, Mazor Z, Stahelin HB. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of 65 ml/min. Osteoporos Int. 5;16:198-3. 28. Dukas LC, Schacht E, Mazor Z, Stahelin HB. A new significant and independent risk factor for falls in elderly men and women: a low creatinine clearance of less than 65 ml/min. Osteoporos Int. 5;16:332-338. 29. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res. ;15: 1113-1118.. Janssen HC, Samson MM, Meeuwsen IB, Duursma SA, Verhaar HJ. Strength, mobility and falling in women referred to a geriatric outpatient clinic. Aging Clin Exp Res. 4;16:122-125. 31. Rantanen T, Era P, Heikkinen E. Physical activity and the changes in maximal isometric strength in men and women from the age of 75 to years. J Am Geriatr Soc. 1997;45:1439-1445. 32. O Loughlin JL, Robitaille Y, Boivin JF, Suissa S. Incidence of and risk factors for falls and injurious falls among the community-dwelling elderly. Am J Epidemiol. 1993;137:342-354. 33. Cummings SR, Nevitt MC, Kidd S. Forgetting falls: the limited accuracy of recall of falls in the elderly. J Am Geriatr Soc. 1988;36:613-616. 34. Dinger MK, Oman RF, Taylor EL, Vesely SK, Able J. Stability and convergent validity of the Physical Activity Scale for the Elderly (PASE). J Sports Med Phys Fitness. 4;44:186-192. 35. Close J, Ellis M, Hooper R, Glucksman E, Jackson S, Swift C. Prevention of falls in the elderly trial (PROFET): a randomized controlled trial. Lancet. 1999;353: 93-97. 36. Wolf SL, Barnhart HX, Kutner NG, McNeely E, Coogler C, Xu T; Atlanta FICSIT Group. Reducing frailty and falls in older persons: an investigation of Tai Chi and computerized balance training: Frailty and Injuries: Cooperative Studies of Intervention Techniques. J Am Geriatr Soc. 1996;44:489-497. 37. Province MA, Hadley EC, Hornbrook MC, et al. The effects of exercise on falls in elderly patients: a preplanned meta-analysis of the FICSIT trials: Frailty and Injuries: Cooperative Studies of Intervention Techniques. JAMA. 1995;273: 1341-1347. 4